Jun Activation Domain Binding Protein 1 Expression Is Associated with Low p27Kip1 Levels in Node-Negative Breast Cancer

Clinical Cancer Research

Volumn 9, Issue 15, 2003, Pages 5652-5659

  Esteva, Francisco J ^a   Sahin, Aysegul A ^a   Rassidakis, George Z ^a   Yuan, Linda X H ^a   Smith, Terry L ^a   Yang, Ying ^a   Gilcrease, Michael Z ^a   Cristofanilli, Massimo ^a   Nahta, Rita ^a   Pusztai, Lajos ^a   Claret, François Xavier ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; JUN ACTIVATION DOMAIN BINDING PROTEIN 1; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE SECTION; TUMOR VOLUME; WESTERN BLOTTING;

BREAST NEOPLASMS; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHATIC METASTASIS; MIDDLE AGED; PEPTIDE HYDROLASES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS; TIME FACTORS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 0344629812     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. 1, cyclin-dependent kinases. Genes Dev., 9: 1149-1163, 1995.
2. Polyak, K., Lee, M. H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., and Massague, J. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 59-66, 1994.
3. 1, cyclin-Cdk protein kinase activity, is related to p21. Cell, 78: 67-74, 1994.
4. Fero, M. L., Randel, E., Gurley, K. E., Roberts, J. M., and Kemp, C. J. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature (Lond.), 396: 177-180, 1998.
5. Catzavelos, C., Bhattacharya, N., Ung, Y. C., Wilson, J. A., Roncari, L., Sandhu, C., Shaw, P., Yeger, H., Morava-Protzner, I., Kapusta, L., Franssen, E., Pritchard, K. I., and Slingerland, J. M. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat. Med., 3: 227-230, 1997.
6. Tan, P., Cady, B., Wanner, M., Worland, P., Cukor, B., Magi-Galluzzi, C., Lavin, P., Draetta, G., Pagano, M., and Loda, M. The cell cycle inhibitor p27 is an independent prognostic marker in small (Tla, b) invasive breast carcinomas. Cancer Res., 57: 1259-1263, 1997.
7. Tsuchiya, A., Zhang, G. J., and Kanno, M. Prognostic impact of cyclin-dependent kinase inhibitor p27kip1 in node-positive breast cancer. J. Surg. Oncol., 70: 230-234, 1999.
8. Barbareschi, M., van Tinteren, H., Mauri, F. A., Veronese, S., Peterse, H., Maisonneuve, P., Caffo, O., Scaioli, M., Doglioni, C., Galligioni, E., Dalla Palma, P., and Michalides, R. P27(Kip1) expression in breast carcinomas: an immunohistochemical study on 512 patients with long-term follow-up. Int. J. Cancer, 89: 236-241, 2000.
9. Claret, F. X., Hibi, M., Dhut, S., Toda, T., and Karin, M. A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature (Lond.), 383: 453-457, 1996.
10. Tomoda, K., Kubota, Y., Arata, Y., Mori, S., Maeda, M., Tanaka, T., Yoshida, M., Yoneda-Kato, N., and Kato, J. Y. The cytoplasmic shuttling and subsequent degradation of p27Kip1 mediated by Jab1/CSN5 and the COP9 signalosome complex. J. Biol. Chem., 277: 2302-2310, 2002.
11. Esteva, F. J., Sahin, A. A., Cristofanilli, M., Arun, B., and Hortobagyi, G. N. Molecular prognostic factors for breast cancer metastasis and survival. Semin. Radiat. Oncol., 12: 319-328, 2002.
12. Kouvaraki, M., Gorgoulis, V. G., Rassidakis, G. Z., Liodis, P., Markopoulos, C., Gogas, J., and Kittas, C. High expression levels of p27 correlate with lymph node status in a subset of advanced invasive breast carcinomas: relation to E-cadherin alterations, proliferative activity, and ploidy of the tumors. Cancer (Phila.), 94: 2454-2465, 2002.
13. Wu, J., Shen, Z. Z., Lu, J. S., Jiang, M., Han, Q. X., Fontana, J. A., Barsky, S. H., and Shao, Z. M. Prognostic role of p27Kip1 and apoptosis in human breast cancer. Br. J. Cancer, 79: 1572-1578, 1999.
14. Newman, L., Xia, W., Yang, H. Y., Sahin, A., Bondy, M., Lukmanji, F., Hung, M. C., and Lee, M. H. Correlation of p27 protein expression with HER-2/ neu expression in breast cancer. Mol. Carcinog., 30: 169-175, 2001.
15. Hoang, M. P., Sahin. A. A., Ordonez, N. G., and Sneige, N. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am. J. Clin. Pathol., 113: 852-859, 2000.
16. Wang, J. Z., Buchholz, T. A., Middleton, L. P., Allred, D. C., Tucker, S. L., Kuerer, H. M., Esteva, F. J., Hortobagyi, G. N., and Sahin, A. A. Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma. Cancer (Phila.), 94: 3107-3114, 2002.
17. Yang, H. Y., Zhou, B. P., Hung, M. C., and Lee, M. H. Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27. J. Biol. Chem., 275: 24735-24739, 2000.
18. Yang, H. Y., Shao, R. P., Hung, M. C., and Lee, M. H. p27 Kip1 inhibits HER2/neu-mediated cell growth and tumorigenesis. Oncogene, 20: 3695-3702, 2001.
19. 0 patients with long-term follow-up. J. Clin. Oncol., 11: 2090-2100, 1993.
20. Fisher, E. R., Anderson, S., Redmond, C., Fisher, B., and NSABP Pathologic findings from the National Surgical Adjuvant Breast Project Protocol B-06. 10-year pathologic and clinical prognostic discriminants. Cancer (Phila.), 71: 2507-2514, 1993.
21. Tomoda, K., Kubota, Y., and Kato, J. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature (Lond.), 398: 160-165, 1999.
22. Hengst, L., and Reed, S. I. Translational control of p27Kip1 accumulation during the cell cycle. Science (Wash. DC), 271: 1861-1864, 1996.
23. Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F., and Rolfe, M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (Wash. DC), 269: 682-685, 1995.
24. Montagnoli, A., Fiore, F., Eytan, E., Carrano, A. C., Draetta, G. F., Hershko, A., and Pagano, M. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev., 13: 1181-1189, 1999.
25. Carrano, A. C., Eytan, E., Hershko, A., and Pagano, M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell. Biol., 1: 193-199, 1999.
26. Sutterluty, H., Chatelain, E., Marti, A., Wirbelauer, C., Senften, M., Muller, U., and Krek, W. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat. Cell. Biol., 1: 207-214, 1999.
27. 187 in p27. Curr. Biol., 9: 661-664, 1999.
28. Sui, L., Dong, Y., Ohno, M., Watanabe, Y., Sugimoto, K., Tai, Y., and Tokuda, M. Jab 1 expression is associated with inverse expression of p27(kip1) and poor prognosis in epithelial ovarian tumors. Clin. Cancer Res., 7: 4130-4135, 2001.
29. Bae, M. K., Ahn, M. Y., Jeong, J. W., Bae, M. H., Lee, Y. M., Bae, S. K., Park, J. W., Kim, K. R., and Kim, K. W. Jab1 interacts directly with HIF-1α and regulates its stability. J. Biol. Chem., 277: 9-12, 2002.
30. Bech-Otschir, D., Kraft, R., Huang, X., Henklein, P., Kapelari, B., Pollmann, C., and Dubiel, W. COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J., 20: 1630-1639, 2001.
31. Wan, M., Cao, X., Wu, Y., Bai, S., Wu, L., Shi, X., Wang, N., and Cao, X. Jab1 antagonizes TGF-β signaling by inducing Smad4 degradation. EMBO Rep., 3: 171-176, 2002.
32. Reed, W., Florems, V. A., Holm, R., Hannisdal, E., and Nesland, J. M. Elevated levels of p27, p21 and cyclin D1 correlate with positive oestrogen and progesterone receptor status in node-negative breast carcinoma patients. Virch. Arch., 435: 116-124, 1999.
33. Porter, P. L., Malone, K. E., Heagerty, P. J., Alexander, G. M., Gatti, L. A., Firpo, E. J., Daling, J. R., and Roberts, J. M. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med., 3: 222-225, 1997.
34. Volpi, A., De Paola, F., Nanni, O., Granato, A. M., Bajorko, P., Becciolini, A., Scarpi, E., Riccobon, A., Balzi, M., and Amadori, D. Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study. Breast Cancer Res. Treat., 63: 181-192, 2000.
35. Leivonen, M., Nordling, S., Lundin, J., von Boguslawski, K., and Haglund, C. p27 expression correlates with short-term, but not with long-term prognosis in breast cancer. Breast Cancer Res. Treat., 67: 15-22, 2001.
36. Gillett, C. E., Smith, P., Peters, G., Lu, X., and Barnes, D. M. Cyclin-dependent kinase inhibitor p27Kip1 expression and interaction with other cell cycle-associated proteins in mammary carcinoma. J. Pathol., 187: 200-206, 1999.
37. Fredersdorf, S., Burns, J., Milne, A. M., Packham, G., Fallis, L., Gillett, C. E., Royds, J. A., Peston, D., Hall, P. A., Hanby, A. M., Barnes, D. M., Shousha, S., O'Hare, M. J., and Lu, X. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc. Natl. Acad. Sci. USA, 94: 6380-6385, 1997.
38. Leong, A. C., Hanby, A. M., Potts, H. W., Tan, D. S., Skilton, D., Ryder, K., Harris, W. H., Liebmann, R. D., Barnes, D. M., and Gillett, C. E. Cell cycle proteins do not predict outcome in grade I infiltrating ductal carcinoma of the breast. Int. J. Cancer, 89: 26-31, 2000.
39. Spataro, V. J., Litman, H., Viale, G., Maffini, F., Masullo, M., Golouh, R., Martinez-Tello, F. J., Grigolato, P., Shilkin, K. B., Gusterson, B. A., Castiglione-Gertsch, M., Price, K., Lindtner, J., Cortes-Funes, H., Simoncini, E., Byrne, M. J., Collins, J., Gelber, R. D., Coates, A. S., and Goldhirsch, A. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status. Cancer (Phila.), 97: 1591-1600, 2003.
40. Nohara, T., Ryo, T., Iwamoto, S., Gon, G., and Tanigawa, N. Expression of cell-cycle regulator p27 is correlated to the prognosis and ER expression in breast carcinoma patients. Oncology, 60: 94-100, 2001.
41. 1 arrest. Nat. Med., 8: 1153-1160, 2002.